Welcome to our dedicated page for Palvella Therapeutics news (Ticker: PVLA), a resource for investors and traders seeking the latest updates and insights on Palvella Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palvella Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palvella Therapeutics's position in the market.
Palvella Therapeutics has completed its merger with Pieris Pharmaceuticals and will trade on Nasdaq as PVLA. The company raised $78.9 million in a private placement co-led by BVF Partners and Frazier Life Sciences. With approximately $80.0 million in cash, operations are funded into second half of 2027.
The company's lead product, QTORIN™ rapamycin, is being developed for microcystic lymphatic malformations (LMs) and cutaneous venous malformations. The drug has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug Designations. A Phase 3 SELVA trial for microcystic LMs is currently enrolling approximately 40 subjects.
Post-merger, former Pieris stockholders own 11% and Palvella stockholders hold 89% of the combined company. The merger was approved by both companies' stockholders in December 2024.
FAQ
What is the current stock price of Palvella Therapeutics (PVLA)?
What is the market cap of Palvella Therapeutics (PVLA)?
